Close
ACHEMA MIDDLE EAST 2026

Global Biopharma Market to Hit $566B by 2032

Global Biopharma Market Forecasts $566B By 2032 opposing Challenges With a compound annual growth rate of almost 8%, from $263 billion in 2022 to $566...

LAI Antipsychotic – Given The Green Light Across The EU

It is indeed worth noting the fact that the first once-every-two-months long-acting injectable- LAI antipsychotic, given a nod by the European Commission- EC is...

NHS Gives Its Nod To New Endometrial Cancer Immunotherapy

The NHS is all set to come up with groundbreaking immunotherapy that can go on to potentially offer a significant additional time when it...

EMA Given Aid To Support African Medicines Agency Setup

The European Medicines Agency- EMA went on to announce on January 26, 2024, that the European Commission-EC has gone ahead and given the agency...

EU Pharma Legislation Reform Aims For Affordable Medicines

The European Commission has proposed a reform of the EU's pharmaceutical legislation with the primary aim of ensuring affordable and accessible medicines in member...

Buyouts Dwindle As Pharma Sector Faces Pricing Concerns

The pharmaceutical industry is currently facing various challenges, including concerns about pricing due to the Inflation Reduction Act and increased scrutiny from the Federal...

Unconstitutional Price-Setting Provisions: PhRMA Asserts

NICA, PhRMA, and GCCA lodged a complaint in the U.S. District Court for the Western District of Texas, asserting that the price setting provisions...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...